drugset
drugset / Trial / NCT01582347

Transfer of Subjects From Subutex/Suboxone to RBP-6300

NCT01582347 ↗

Phase 2 Completed 143 enrolled Indivior Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to determine if opioid dependent subjects who are already receiving Subutex and/or Suboxone can transfer to RBP-6300. Upon completing the study, subjects will continue their pre-study prescribed dosage of Subutex and/or Suboxone

Timeline

Start
2012-03
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 8 mg Other
Subject Buprenorphine Other / unclassified 16 mg Other
Subject Buprenorphine Other / unclassified 24 mg Other
Subject Naloxone Small molecule 2 mg Other
Subject RBP-6300 Unknown 10 mg Oral
Subject RBP-6300 Unknown 20 mg Oral
Subject RBP-6300 Unknown 30 mg Oral

Indications

opiate dependence